Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for th...

詳細記述

保存先:
書誌詳細
出版年:Clin Infect Dis
主要な著者: Titanji, Boghuma K, Farley, Monica M, Mehta, Ashish, Connor-Schuler, Randi, Moanna, Abeer, Cribbs, Sushma K, O’Shea, Jesse, DeSilva, Kathryn, Chan, Bonnie, Edwards, Alex, Gavegnano, Christina, Schinazi, Raymond F, Marconi, Vincent C
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2020
主題:
Brief Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7337637/
https://ncbi.nlm.nih.gov/pubmed/32597466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa879
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料